Compare Knight-Swift Transportation Holdings Inc. (KNX) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Knight-Swift Transportation Holdings Inc. vs Mesoblast Limited — how do they compare? Knight-Swift Transportation Holdings Inc. trades at $64.47 (market cap $10.59B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Knight-Swift Transportation Holdings Inc. is far larger — about 6.1× Mesoblast Limited's market cap, and Knight-Swift Transportation Holdings Inc. pays a 1.23% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Knight-Swift Transportation Holdings Inc. for 1 Days and Mesoblast Limited for 15 Days on average.
| KNX | MESO | |
|---|---|---|
Market Cap | $10.59B | $1.75B |
Volume | 2,972,511 | 239,027 |
Sector | Industrials | Health |
52-Week High | $82.45 | $20.96 |
52-Week Low | $41.68 | $13.19 |
Typical Hold Time | 1 Days | 15 Days |
Enterprise Value | $13.09B | $1.83B |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Knight-Swift Transportation Holdings Inc.
Knight-Swift provides truckload, less-than-truckload, logistics, and freight management services. It operates a large transportation network across North America.
Read more on KNX →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
